Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies

Clinical Transplantation

Volumn 19, Issue 1, 2005, Pages 61-69

  Anil Kumar, Mysore S ^a   Xiao, Sheng Guang ^a   Fyfe, Billie ^a   Sierka, Debra ^a   Heifets, Michael ^a   Moritz, Michael J ^a   Saeed, Muhammad I ^a   Kumar, Aparna ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

African American; Cadaveric organs; Kidney transplantation; Post transplantation diabetes; Protocol biopsy; Simulect

Indexed keywords

BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; ARTICLE; BODY WEIGHT DISORDER; CADAVER KIDNEY; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AFRICAN AMERICANS; AGED; ANTIBODIES, MONOCLONAL; BIOPSY; CLINICAL PROTOCOLS; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 13644263690     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00298.x     Document Type: Article

References (21)

1. Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001: 72: SS75.
2. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999: 33: 829.
3. Matas AJ, Ramcharan T, Paraskevas S et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001: 1: 278.
4. Kumar MSA, Fa K, Fyfe B et al. Steroid avoidance (SA) in kidney transplant recipients treated with Simulect (Bmab), Neoral (CsA), and CellCept (MMF) - a randomized prospective controlled clinical trial. Am J Transplant 2002: 2: 393 (Abstract 1012).
5. Fa X, Kode RK, Lu Q et al. Value of one month protocol biopsies combined with a molecular analysis in predicting efficacy of rapid steroid withdrawal after renal transplantation. Am J Transplant 2002: 2: 171 (Abstract 132).
6. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
7. Van den Ham ECH, Kooman JP, Christiaans MHL, van Hooff JP. The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transpl Int 2003: 16: 82.
8. Leventhal J, Kaufman D, STuart J et al. Steroid avoidance is safe and effective in high risk renal transplant recipients. Am J Transplant 2002: 2: 173 (Abstract 139).
9. Hricik DE. Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant 2002: 2: 19.
10. Cole E, Landsberg D, Russell D et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001: 72: 845.
11. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003: 3: 306.
12. Chatenoud L, Legendre C, Ferran C, Bach JF, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome - dosage and kinetics prerequisites. Transplantation 1991: 51: 334.
13. Kode R, Fa K, Chowdhury S et al. Basiliximab plus low-dose cyclosporine vs. OKT3 for induction immunosupppression following renal transplantation. Clin Transplant 2003: 17: 369.
14. Rush D, Somorjai R, Deslauriers R, Shaw A, Jeffery J, Nickerson P. Subclinical rejection - a potential surrogate marker for chronic rejection - may be diagnosed by protocol biopsy or urine spectroscopy. Ann Transplant 2000: 5: 44.
15. Matas AJ. Risk factors for chronic rejection - a clinical perspective. Transpl Immunol 1998: 6: 1.
16. Gotti E, Perico N, Perna A et al. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. J Am Soc Nephrol 2003: 14: 755.
17. Ojo AO, Hanson JA, Meier-Kriesche H-U et al. Survival in recipients of marginal cadaveric donor kidneys compared with orther recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001: 12: 589.
18. Neylan JF, For the FK506 Kidney Transplant Study Group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998: 65: 515.
19. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003: 3: 178.
20. Eugui EM. Fibrogenesis in chronic allograft rejection: underlying mechanisms and pharmacologic control. Transplant Proc 2002: 34: 2867.
21. Krieger N, Becker B, Heisey DM et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts. Transplantation 2003: 75: 1677.